{"id":"mrg003-pucotenlimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4650472","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MRG003 functions as a bispecific antibody that simultaneously engages PD-L1 on tumor cells and 4-1BB on T cells, providing dual checkpoint blockade with costimulation. Pucotenlimab is a humanized monoclonal antibody against PD-L1 that prevents interaction with PD-1 and B7.1, further enhancing T-cell proliferation and function. The combination aims to overcome tumor immune evasion through complementary mechanisms of checkpoint inhibition and T-cell costimulation.","oneSentence":"MRG003 is a bispecific antibody targeting PD-L1 and 4-1BB that enhances T-cell activation, while Pucotenlimab is a PD-L1 inhibitor, together blocking immune checkpoints to reinvigorate anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:09.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07464366","phase":"PHASE2","title":"The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Ji Dongmei","startDate":"2026-03-15","conditions":"Salivary Gland Carcinomas","enrollment":68},{"nctId":"NCT07381699","phase":"PHASE2","title":"MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":30},{"nctId":"NCT07394244","phase":"PHASE2","title":"Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-09","conditions":"Cutaneous Squamous Cell Carcinoma (CSCC)","enrollment":38},{"nctId":"NCT06976190","phase":"PHASE3","title":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2025-05-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":446},{"nctId":"NCT07235566","phase":"PHASE2","title":"MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-21","conditions":"Thyroid Cancer","enrollment":60},{"nctId":"NCT06959108","phase":"PHASE2","title":"Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck","status":"NOT_YET_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2025-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":106},{"nctId":"NCT06530914","phase":"PHASE2","title":"A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Lei Liu","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRG003 + Pucotenlimab","genericName":"MRG003 + Pucotenlimab","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRG003 is a bispecific antibody targeting PD-L1 and 4-1BB that enhances T-cell activation, while Pucotenlimab is a PD-L1 inhibitor, together blocking immune checkpoints to reinvigorate anti-tumor immunity. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}